MARKET

EIKN

EIKN

Eikon Therapeutics
NASDAQ
9.21
-0.41
-4.26%
After Hours: 9.43 +0.22 +2.39% 19:34 07/31 EDT
OPEN
9.54
PREV CLOSE
9.62
HIGH
9.66
LOW
8.98
VOLUME
235.38K
TURNOVER
--
52 WEEK HIGH
17.40
52 WEEK LOW
7.90
MARKET CAP
498.62M
P/E (TTM)
-2.3393
1D
5D
1M
3M
1Y
5Y
1D
Eikon Doses First Patient In Phase 2/3 TeLuRide For EIK1001 For NSCLC; Stock Up
NASDAQ · 6d ago
Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks Moving Higher On Monday
Benzinga · 6d ago
Eikon Therapeutics Shares Up on First Dose to Patient in Phase 2/3 Lung Cancer Trial
Dow Jones · 6d ago
Eikon Therapeutics doses first patient in TeLuRide-008 study
TipRanks · 6d ago
Eikon Therapeutics Doses First Patient In TeLurRide-008, A Phase 2/3 Registrational Study Of EIK1001 In Combination With Pembrolizumab And Histology-Appropriate Chemotherapy For Stage 4 Non-Small Cell Lung Cancer
Benzinga · 6d ago
Eikon Therapeutics doses first patient in TeLuRide-008 Phase 2/3 NSCLC trial of EIK1001 combo
PUBT · 6d ago
EIKON THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN TELURIDE-008, A REGISTRATIONAL PHASE 2/3 TRIAL OF EIK1001 IN NON-SMALL CELL LUNG CANCER
Reuters · 6d ago
Weekly Report: what happened at EIKN last week (0720-0724)?
Weekly Report · 6d ago
More
About EIKN
Eikon Therapeutics, Inc. is a late-stage clinical biopharmaceutical company, which is focused on advancing a pipeline of potential therapies for patients with unmet medical needs. The Company has clinical programs at various stages of development, and active discovery efforts in oncology and neurological disease. Its pipeline includes EIK1001 TLR7/8 Melanoma, EIK1001 TLR7/8 NSCLC, EIK1003 PARP1, EIK1004 PARP1, EIK1005 WRN Phase 1, EIK1006, and AR-V7. EIK1001 is a systemically administered dual-agonist of toll-like receptors 7 and 8 that has demonstrated single-agent activity, as well as activity in combination with anti-PD-(L)1 agents, across multiple solid tumor types in Phase 1 trials. EIK1003 targets PARP1, a central component of DNA repair machinery in normal cells. EIK1003 is being evaluated in a Phase 1/2 study of patients with breast, ovarian, or prostate malignancies that have known or suspected deleterious mutations of select homologous recombination repair (HRR) genes.

Webull offers Eikon Therapeutics,Inc stock information, including NASDAQ: EIKN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EIKN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EIKN stock methods without spending real money on the virtual paper trading platform.